Top-line results from a Phase 2 trial of TX45, Tectonic Therapeutics’ experimental drug for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), are expected late this year or early next year, the company said. The trial, APEX…
Mannkind said it is creating an inhaled formulation of ralinepag, an experimental oral pulmonary arterial hypertension (PAH) treatment, for developer United Therapeutics. The inhaled version, ralinepag DPI, will be a dry powder that delivers the drug directly to the lungs, providing an alternative to the tablet formulation. The…
Treatment with treprostinil, a medicine that relaxes blood vessels, led to significant and sustained improvements in children with pulmonary hypertension (PH) caused by different lung conditions, according to a retrospective analysis. Findings from the analysis were detailed in the study, “Treprostinil Is Associated With Early and Sustained Improvement…
A team of scientists in China identified four genes that may serve as potential treatment targets for idiopathic pulmonary arterial hypertension (PAH). “This study combined [computer-based genetic sequencing] analyses with experimental validation [in cell and animal models] to identify COL1A1, MYL9, COL1A2, and TPM2 as potential key driver genes…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
